- Home
- KNOP vs TVGN Comparison
KNOP vs TVGN Comparison
Compare KNOP & TVGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | KNOP | TVGN |
|---|---|---|
| Founded | 2013 | 2020 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Blank Checks |
| Sector | Consumer Discretionary | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 346.6M | 89.6M |
| IPO Year | 2013 | N/A |
Fundamental Metrics
Financial Performance| Metric | KNOP | TVGN |
|---|---|---|
| Price | $10.13 | $0.39 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | N/A | ★ $5.00 |
| AVG Volume (30 Days) | 112.0K | ★ 1.5M |
| Earning Date | 12-04-2025 | 11-14-2025 |
| Dividend Yield | ★ 1.01% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 1.17 | N/A |
| Revenue | ★ $352,712,000.00 | N/A |
| Revenue This Year | $14.84 | N/A |
| Revenue Next Year | $1.98 | N/A |
| P/E Ratio | $8.83 | ★ N/A |
| Revenue Growth | ★ 17.65 | N/A |
| 52 Week Low | $5.29 | $0.30 |
| 52 Week High | $10.99 | $1.92 |
Technical Indicators
Market Signals| Indicator | KNOP | TVGN |
|---|---|---|
| Relative Strength Index (RSI) | 46.58 | 47.91 |
| Support Level | $10.06 | $0.34 |
| Resistance Level | $10.53 | $0.38 |
| Average True Range (ATR) | 0.23 | 0.03 |
| MACD | -0.06 | 0.00 |
| Stochastic Oscillator | 20.61 | 80.73 |
Price Performance
Historical ComparisonAbout KNOP KNOT Offshore Partners LP
KNOT Offshore Partners LP owns, operates, and shuttles tankers under long-term charters in the North Sea and Brazil. The company provides crude oil loading, transportation, and storage services under time charters and bareboat charters. The Partnership is formed for acquiring ownership interests in over four shuttle tankers owned by Knutsen NYK Offshore Tankers AS (KNOT). It operates through the shuttle tanker market segment.
About TVGN Tevogen Bio Holdings Inc.
Tevogen Bio Holdings Inc a clinical-stage specialty immunotherapy company harnessing CD8+ cytotoxic T lymphocytes (CD8+ CTLs or CTLs), to develop off-the-shelf, precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders.